Ono Pharmaceutical Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ono Pharmaceutical Co. sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Ono Pharmaceutical Co.: 17 sponsored US clinical trials, 5 recruiting.
Ono Pharmaceutical Co. sponsors 17 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary CNS Lymphoma, with 1 trials.
Top-decile sponsor footprint
Ono Pharmaceutical Co. ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
17 total, page 1 of 1
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
NCT07198087
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
NCT05515406
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
A Phase 1 Study of ONO-2020 in Healthy Participants
NCT05507515
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
NCT03571594
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
NCT03182257
A Study of ONO-7475 in Patients With Acute Leukemias
NCT03176277
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569242
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
NCT02083289
ONO-7746 Study in Healthy Adult Subject
NCT01106664
ONO-7746 Study in Healthy Adult Subjects
NCT00956371
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Ono Pharmaceutical Co. pipeline
5 recruiting of 17 indexed (29% open); 5 completed (29%).
Phase mix: 3 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Primary CNS Lymphoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ono Pharmaceutical Co.: open-pipeline peers nationwide
Peers matched on 17 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Ono Pharmaceutical Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Children's Hospital Los Angeles · 29% recruiting · 119 trials
- Natural Immune Systems · 29% recruiting · 17 trials
- Queen's Medical Center · 29% recruiting · 17 trials
- Inova Health Care Services · 29% recruiting · 75 trials
Related
What to do with this Ono Pharmaceutical Co. page
17 registered trials is a research-attention snapshot, not an endorsement of Ono Pharmaceutical Co. or any single study.
- 5 of Ono Pharmaceutical Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary CNS Lymphoma is the condition Ono Pharmaceutical Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary CNS Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ono Pharmaceutical Co. pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.